- After decades of neglect, sickle cell disease could soon be transformed with gene-based therapies The Boston Globe
- FDA Accepts Vertex (VRTX), CRISPR’s BLA Filings for Exa-Cel Yahoo Finance
- Editas charts plan for sickle cell CRISPR therapy amid competition STAT
- CRSP Stock Pops As FDA Sets December Data To Potentially OK Gene-Editing Drug | Investor’s Business Daily Investor’s Business Daily
- Vertex/CRISPR Partnered Cell Therapy Shows Encouraging Response In Sickle Cell Disease, Thalassemia Patients Yahoo Finance
- View Full Coverage on Google News
Read More: After decades of neglect, sickle cell disease could soon be transformed with